Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: A meta-analysis

Drugs

Volumn 72, Issue 18, 2012, Pages 2365-2373

  De Vries, Folgerdiena M ^a   Denig, Petra ^b   Pouwels, Koen B ^a   Postma, Maarten J ^a   Hak, Eelko ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disorders; Cerebrovascular disorders; Diabetes mellitus; HMG CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84871202527     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11638240-000000000-00000     Document Type: Review

References (33)

1. World Health Organisation. Global health observatory; causes of death in 2008. online. Available from URL; :http://www.who.int/gho/mortality-burden- disease/causes-death-2008/en/index.html. Accessed 2012 Jan 18.
2. American Heart Association. Cardiovascular disease and diabetes; statistics update 2010. online. Available from URL; :http://www.heart.org/ HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes- UCM-313865-Article.jsp. Accessed 2012 Jan 18.
3. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 1998 Jan; 21 (1); 69-75
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment; prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct; 366 (9493); 1267-78
5. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care; cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005 Apr 9; 330 (7495); 821
6. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011 Jan 19; (1); CD004816
7. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18 a686 people with diabetes in 14 randomised trials of statins; a meta-analysis. Lancet 2008 Jan 12; 371; 117-25
8. Knopp RH, D'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes; the Atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006 Jul; 29 (7); 1478-85
9. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors; meta-analysis of randomised controlled trials. BMJ 2009 Jun 30; 338; b2376
10. Chen YH, Feng B, Chen ZW. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases; a meta-analysis. Exp Clin Endocrinol Diabetes 2012 Feb; 120 (2); 116-20
11. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER); a randomised controlled trial. Lancet 2002 Nov 23; 360 (9346); 1623-30
12. Jüni P, Altman DG, Egger M. Systematic reviews in health care; Assessing the quality of controlled clinical trials. BMJ 2001 Jun 7; 323 (7303); 42-6
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials; is blinding necessary? Control Clin Trials 1996 Feb; 17 (1); 1-12
14. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes. Diabetes Care 2005 May; 28; 1151-7
15. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS); multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21-27; 364; 685-96
16. Collins R, Armitage J, Parish S, et al. MRC BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes; a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361 (9374); 2005-16
17. Cook RJ, Sackett D. The number needed to treat; a clinically useful measure of treatment. BMJ 1995 Feb 18; 310 (6977); 452-4
18. Scholten RJ, Kostense PJ, Assendelften WJ, et al. The practice of systematic reviews; IV. Pooling results from separate studies. in Dutch. Ned Tijdschr Geneeskd 1999; 143; 786-91
19. Review manager (RevMan). computer program. Version 5.1. Copenhagen; The Nordic Cochrane Centre, The Cochrane Collaboration, 2011
20. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. Part 3 fixed-effect versus random effects models. Chichester; John Wiley & Sons, Ltd, 2009; 59-86
21. Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008 Nov 27; 8; 79
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327 (7414); 557-60
23. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care; the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288 (23); 2998-3007.
24. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study); a prospective randomised controlled trial. Lancet 2006 Sep 30; 368 (9542); 1155-63
25. Wanner C, Krane V, Marz W, et al., German Diabetes and Dialysis Study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 2005; 353; 238-48
26. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998 Mar 1; 81 (5); 582-7
27. Grundy S, Cleeman JI, Merz NB, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials of the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul 13; 100 (2); 227-39
28. Reiner Z, Catapano AL, De Backer G, et al. ESC EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul; 32 (14); 1769-818
29. Rutten GEHM, De Grauw WJC, Nijpels G. NHG-Standaard diabetes mellitus type 2. Huisarts Wet 2006; 49 (3); 137-52
30. Wiersma TJ, Goudswaard AN. NHG-standard cardiovascular risk management. in Dutch. Houten; Bohn Stafleu van Loghum, 2006
31. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy; a major challenge for preventive cardiology. Expert Opin Pharmacother 2009 Dec; 10 (18); 2973-85
32. Donnelly LA, Doney ASF, Morris AD. Long-term adherence to statin treatment in diabetes. Diabetic Med 2008; 25 (7); 850-5
33. Olafsdottir E, Aspelund T, Sigurdsson G, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older patients; the population-based AGES-Reykjavik Study. BMJ Open 2011 Jan 1; 1 (1); e000132